New Edge Advisors, LLC Pharma Cyte Biotech, Inc. Transaction History
New Edge Advisors, LLC
- $15 Billion
- Q3 2024
A detailed history of New Edge Advisors, LLC transactions in Pharma Cyte Biotech, Inc. stock. As of the latest transaction made, New Edge Advisors, LLC holds 2 shares of PMCB stock, worth $3. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2
Previous 2
-0.0%
Holding current value
$3
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding PMCB
# of Institutions
30Shares Held
932KCall Options Held
0Put Options Held
0-
K2 Principal Fund, L.P. Toronto, A6209KShares$355,7520.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA192KShares$327,0570.0% of portfolio
-
Geode Capital Management, LLC Boston, MA168KShares$285,9400.0% of portfolio
-
Ayrton Capital LLC Westport, CT92.1KShares$156,5477.31% of portfolio
-
Equitec Proprietary Markets, LLC82.7KShares$140,6350.17% of portfolio
About PharmaCyte Biotech, Inc.
- Ticker PMCB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,750,100
- Market Cap $35.3M
- Description
- PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types o...